Biotechnology

Viewpoint Molecular Targeting Announces Two New Grant Awards of $2 Million Each

October 11, 2022 8:00 AM

SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer Institute CORALVILLE, IA / ACCESSWIRE / October 11, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the award of two...

Read more

Eyam Announces Partnership with Mitacs to Fund Next Generation COVID-19 Vaccine Technologies

October 11, 2022 7:30 AM

VANCOUVER, BC / ACCESSWIRE / October 11, 2022 / Eyam Vaccines and Immunotherapeutics ltd. ("Eyam" or the "Company"), today announced a partnership with Mitacs to fund Post-Doctoral Fellowships at the University of British Columbia (UBC). Mitacs, is a not-for-profit organization that fosters growth and innovation, and will provide equal funding for research efforts at UBC that will directly support Eyam's leading vaccine development programs for...

Read more

Vaso Corporation Announces Up-listing to OTCQB Market

October 6, 2022 9:00 AM

PLAINVIEW, NY / ACCESSWIRE / October 6, 2022 / Vaso Corporation ("Vaso") (OTCMKTS:VASO) today announced that its application to up-list from the OTC Pink Sheets to the OTCQB market has been approved by OTC Markets Group. The effective date of the listing on OTCQB is expected to be on October 10, 2022. Compared to the OTC Pink Sheets, listing on the OTCQB market significantly increases transparency, reporting standards, management certification...

Read more

Plandai Biotechnologies, Inc. Announces Entry into Non-Binding Letter of Intent, Updates on Status of Independent Audit

October 6, 2022 6:00 AM

SAN DIEGO, CA / ACCESSWIRE / October 6, 2022 / (OTC PINK:PLPL) - Plandai Biotechnology, Inc. ("Plandai" or the "Company") announces its entry into a non-binding letter of intent with EV Hotel Corp., a Georgia corporation. EV Hotel™ developed the world's first proprietary disruptive hospitality platform - the "smart hotel," combining technology, automation, IoT, crypto and NFT with best-in-class service, stylish design, and upscale amenities to...

Read more

Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study

October 5, 2022 6:30 AM

COLLEGE STATION, TX / ACCESSWIRE / October 5, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). The Company announces the completion of the first phase of the animal toxicology studies on its ITV-1 anti-HIV therapeutic. The initial toxicology study showed "no adverse effects at maximal dose of the product" and confirmed the product is safe at maximum dose, leading the way for a GLP Compliant 28-day Repeat Dose Toxicity Study....

Read more

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

October 4, 2022 8:00 AM

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, MD to its Scientific Advisory Board. Dr. Tsung is a nationally and internationally recognized leader specializing in evaluating and caring for patients with...

Read more

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

October 4, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company focused on the development of monoclonal antibodies targeting various cancer types, announced today that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab ("PTB") as a treatment for Primary and...

Read more

Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer

October 4, 2022 8:00 AM

Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs CORALVILLE, IA / ACCESSWIRE / October 4, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of...

Read more

China Dasheng Biotechnology Co. Accepts Effective Control of Cycclone Magnetic Engine Developments Limited

October 3, 2022 3:30 PM

ARUNDEL, QUEENSLAND / ACCESSWIRE / October 3, 2022 / China Dasheng Biotechnology Co. (OTC:CDBT) to be renamed Cycclone Magnetic Engine Developments, Inc., today announced that on October 1, 2022, CDBT accepted effective control of Cycclone Magnetic Engine Developments Limited and the 2 wholly owned subsidiaries, Cycclone Engine Developments Pty Ltd and Y Engine Developments Pty Ltd. Background: On July 19, 2022, joint custodians of CDBT, Mr....

Read more

Viewpoint Molecular Targeting Announces VMT-𝛼-NET Granted U.S. FDA Fast Track Destination for the Treatment of Neuroendocrine Tumors

October 3, 2022 9:00 AM

CORALVILLE, IA / ACCESSWIRE / October 3, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive...

Read more

Media Alert: BrainChip Discusses Advanced Vision Systems with Luca Verre on Latest 'This is our Mission' Podcast

October 3, 2022 9:00 AM

LAGUNA HILLS, CA / ACCESSWIRE / October 3, 2022 / BrainChip Holdings Ltd (ASX:BRN, OTCQX:BRCHF, ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, today announced that Luca Verre, CEO and co-founder of PROPHESEE, is the featured guest on the 20th episode of the "This is our Mission" podcast. He joins BrainChip Vice President of Ecosystem and Partnerships Rob Telson to discuss overcoming roadblocks of computer vision by...

Read more

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

September 30, 2022 8:00 AM

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significant EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo Clinical Study Report submitted to FDA TORONTO, ON / ACCESSWIRE / September 30, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced final results from the Phase 2...

Read more

Viewpoint Molecular Targeting Announces Transformational Merger

September 29, 2022 8:00 AM

CORALVILLE, IA / ACCESSWIRE / September 29, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy. Under the...

Read more

AiCuris Anti-Infective Cures AG: AiCuris´ Innovation Accelerator AiCubator Calls for Innovative Proposals to Propel Anti-Infective Drug Development in The Third Round

September 29, 2022 3:20 AM

The AiCubator program was launched to provide first-hand support to fuel early research projects of young start-ups and academic teams that have the potential to become the next generation of resistance breaking anti-infective therapies Up to three projects will be awarded AiCubator Resident Status and will benefit from financial support, the company's scientific know-how, its proven drug development expertise and its extensive network in the...

Read more

Aqualung Therapeutics Corp. Announces FDA Clearance of Investigational New Drug (IND) Application for ALT-100, a Novel mAb Therapy for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

September 26, 2022 10:15 AM

- Aqualung will continue the P1A Healthy Human Volunteer Trial and complete the trial first half of 2023 - The Phase 2A study (PUERTA) will be initiated in the 2nd half of 2023 - ALT-100 is the first humanized mAb therapy that targets the eNAMPT protein which plays a pivotal role in regulating inflammation and fibrosis TUCSON, AZ / ACCESSWIRE / September 26, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company today announced that...

Read more

Black Bird Biotech To Formally Test MiteXstream Biopesticide for Capacity to Boost Plant Growth, Fruit Production, In Common Agricultural Crops

September 26, 2022 9:25 AM

FLOWER MOUND, TX / ACCESSWIRE / September 26, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that it has begun testing its MiteXstreamTM biopesticide for its demonstrated capacity (1) to assist plants in nutrient absorption or (2) to act as a plant nutrient in tandem with its biopesticide capacity. The testing will determine whether the Company will be in a position...

Read more

Media Alert: BrainChip Demonstrates the Power and Simplicity of Edge AI at Edge Impulse Imagine

September 26, 2022 9:00 AM

LAGUNA HILLS, CA / ACCESSWIRE / September 26, 2022 / Experts from BrainChip Holdings Ltd (ASX:BRN, OTCQX:BRCHF, ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, are speaking to audiences at Edge Impulse Imagine about the company's innovative technology in person at the Computer History Museum in Mountain View, California, and streaming worldwide September 28-30. Rob Telson, BrainChip Vice President of...

Read more

DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging

September 26, 2022 7:00 AM

TORONTO, ON / ACCESSWIRE / September 26, 2022 / DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging. The syndicated investment was co-led by the Angelini Lumira Biosciences Fund and Noetic Fund and included participation from Toronto Innovation Acceleration Partners (TIAP), and...

Read more

TISSIUM Appoints Sara Toyloy as Independent Board Member

September 26, 2022 6:00 AM

PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / September 26, 2022 / TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Sara Toyloy as its fourth independent member of the Board of Directors. Ms. Toyloy has over 30 years of experience in the medical device industry. In 2020, she founded Fabrica Consulting LLC, a medical device consulting firm providing...

Read more

NovAccess Global Announces Effectiveness of Form S-1 Registration Statement

September 22, 2022 9:00 AM

Includes 7.5 Million Shares for Innovest Global Share Distribution Increases Unaffiliated Float While Significantly Expanding Shareholder Base CLEVELAND, OH / ACCESSWIRE / September 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the Securities and Exchange Commission ("SEC") has declared the Company's registration statement on Form S-1 effective...

Read more